{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:03:07Z","timestamp":1750996987559,"version":"3.41.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"DOI":"10.1007\/s10689-025-00458-8","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:07:22Z","timestamp":1743120442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Endometrial thickness among BRCA mutation carriers undergoing prophylactic oophorectomy"],"prefix":"10.1007","volume":"24","author":[{"given":"Michelle","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrianna","family":"Klejnotowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Kotsopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"458_CR1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117\u20131130","journal-title":"Am J Hum Genet"},{"key":"458_CR2","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","volume":"31","author":"KA Phillips","year":"2013","unstructured":"Phillips KA, Milne RL, Rookus MA et al (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31:3091\u20133099","journal-title":"J Clin Oncol"},{"key":"458_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-014-3026-3","volume":"146","author":"J Gronwald","year":"2014","unstructured":"Gronwald J, Robidoux A, Kim-Sing C et al (2014) Duration of Tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 146:421\u2013427","journal-title":"Breast Cancer Res Treat"},{"key":"458_CR4","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","volume":"356","author":"SA Narod","year":"2000","unstructured":"Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary breast cancer clinical study group. Lancet 356:1876\u20131881","journal-title":"Lancet"},{"key":"458_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP et al (2021) Genetic\/Familial High-Risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19:77\u2013102","journal-title":"J Natl Compr Canc Netw"},{"key":"458_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ygyno.2022.01.014","volume":"164","author":"YY Xia","year":"2022","unstructured":"Xia YY, Gronwald J, Karlan B et al (2022) Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 164:514\u2013521","journal-title":"Gynecol Oncol"},{"key":"458_CR7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ijc.29386","volume":"137","author":"J Kotsopoulos","year":"2015","unstructured":"Kotsopoulos J, Lubinski J, Gronwald J et al (2015) Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer 137:1136\u20131146","journal-title":"Int J Cancer"},{"key":"458_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/jnci\/djab036","volume":"113","author":"MM de Jonge","year":"2021","unstructured":"de Jonge MM, de Kroon CD, Jenner DJ et al (2021) Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: multicenter cohort study. J Natl Cancer Inst 113:1203\u20131211","journal-title":"J Natl Cancer Inst"},{"key":"458_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2013.03.027","volume":"130","author":"Y Segev","year":"2013","unstructured":"Segev Y, Iqbal J, Lubinski J et al (2013) The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 130:127\u2013131","journal-title":"Gynecol Oncol"},{"key":"458_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10689-015-9798-8","volume":"14","author":"Y Segev","year":"2015","unstructured":"Segev Y, Rosen B, Lubinski J et al (2015) Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Fam Cancer 14:383\u2013391","journal-title":"Fam Cancer"},{"key":"458_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0029-1242998","volume":"28","author":"JJ Kim","year":"2010","unstructured":"Kim JJ, Chapman-Davis E (2010) Role of progesterone in endometrial cancer. Semin Reprod Med 28:81\u201390","journal-title":"Semin Reprod Med"},{"key":"458_CR12","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","volume":"14","author":"M Widschwendter","year":"2013","unstructured":"Widschwendter M, Rosenthal AN, Philpott S et al (2013) The sex hormone system in carriers of BRCA1\/2 mutations: a case-control study. Lancet Oncol 14:1226\u20131232","journal-title":"Lancet Oncol"},{"key":"458_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s13224-020-01415-4","volume":"71","author":"SK Giri","year":"2021","unstructured":"Giri SK, Nayak BL, Mohapatra J (2021) Thickened endometrium: when to intervene?? A clinical conundrum. J Obstet Gynaecol India 71:216\u2013225","journal-title":"J Obstet Gynaecol India"},{"key":"458_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1148\/radiographics.21.6.g01nv211409","volume":"21","author":"KM Nalaboff","year":"2001","unstructured":"Nalaboff KM, Pellerito JS, Ben-Levi E (2001) Imaging the endometrium: disease and normal variants. Radiographics 21:1409\u20131424","journal-title":"Radiographics"},{"key":"458_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/bmj.39126.628924.BE","volume":"334","author":"A Sahdev","year":"2007","unstructured":"Sahdev A (2007) Imaging the endometrium in postmenopausal bleeding. BMJ 334:635\u2013636","journal-title":"BMJ"},{"key":"458_CR16","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","volume":"31","author":"VW Setiawan","year":"2013","unstructured":"Setiawan VW, Yang HP, Pike MC et al (2013) Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31:2607\u20132618","journal-title":"J Clin Oncol"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00458-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-025-00458-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00458-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:57:45Z","timestamp":1750913865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-025-00458-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1007\/s10689-025-00458-8","relation":{},"ISSN":["1573-7292"],"issn-type":[{"type":"electronic","value":"1573-7292"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}